Senate HELP Committee Passes FDA Reauthorization Bill
Last week, the U.S. Senate Health, Education, Labor and Pensions
(HELP) Committee passed S. 4348, “Food and Drug Administration Safety and Landmark
Advancements Act of 2022” or the “FDASLA Act of 2022,” which would reauthorize
various Food and Drug Administration (FDA) drug and device approval programs.
The FDA negotiates with industries to set the fees for the
drug and device approval programs, along with goals for review times. Congress
then approves the negotiated agreement through the reauthorization process. The
current FDA user fee authorization is set to expire on Sept. 30, 2022. FDA user
fee authorizations generally last for five years.
S. 4348 differs in several areas from H.R. 7667, “Food and Drug Amendments of 2022,” the FDA user
fee reauthorization passed by the House in early June. While both bills agree
on the accelerated approval review times for both brand and generic drugs, there
are differences between the two bills on issues such as clinical trial diversity,
baby formula, diagnostic tests, drug imports from Canada and cosmetics review and safety.
The Senate bill is expected to move to the Senate floor prior to the August recess.